eccogene glp-1 AstraZeneca raises stakes in obesity drug race with deal AstraZeneca targets obesity market with

prioritizes safety above all in weight loss and metabolic care

de Sousa RT, Zarate CA, Zanetti MV, Costa AC, Talib LL, Gattaz WF, et al

T2D independently elevates colorectal cancer risk, though the cumulative impact of both conditions had not previously been studied at scale

You cannot see potency

The experts further explored recommendations in current international treatment guidelines for people with T2D and at high risk for CVD and CKD, perceptions of CKM health as a concept recently motivated by the AHA Presidential Advisory [7], and the influence of existing barriers to early initiation and their impact on therapeutic management, together with optimal care, including integrated and multidisciplinary approaches